748 related articles for article (PubMed ID: 19404048)
21. Statins reduce cardiovascular events in primary and secondary prevention trials without causing an increase in carcinoma.
Aronow WS
J Am Geriatr Soc; 2009 Oct; 57(10):1942-3; author reply 1943-4. PubMed ID: 19807799
[No Abstract] [Full Text] [Related]
22. Lipid-lowering drugs in ischemic stroke prevention and their influence on acute stroke outcome.
Fuentes B; Martínez-Sánchez P; Díez-Tejedor E
Cerebrovasc Dis; 2009; 27 Suppl 1():126-33. PubMed ID: 19342842
[TBL] [Abstract][Full Text] [Related]
23. Statins in the intensive care unit.
Merx MW; Weber C
Curr Opin Crit Care; 2006 Aug; 12(4):309-14. PubMed ID: 16810040
[TBL] [Abstract][Full Text] [Related]
24. Identification of patients at risk of ischemic events for long-term secondary prevention.
Brassard A
J Am Acad Nurse Pract; 2009 Dec; 21(12):677-89. PubMed ID: 19958419
[TBL] [Abstract][Full Text] [Related]
25. Clinical review: impact of statin substitution policies on patient outcomes.
Atar D; Carmena R; Clemmensen P; K-Laflamme A; Wassmann S; Lansberg P; Hobbs R
Ann Med; 2009; 41(4):242-56. PubMed ID: 19191052
[TBL] [Abstract][Full Text] [Related]
26. [Secondary prevention of patients with ischaemic heart disease--the reduction of LDL cholesterol level and the regression of atherosclerosis].
Bárczi G; Merkely B
Lege Artis Med; 2007 Oct; 17(10):675-9. PubMed ID: 19227597
[TBL] [Abstract][Full Text] [Related]
27. Statins for the primary prevention of cardiovascular events in elderly patients: a picture from clinical practice without strong evidence from clinical trials.
Trifirò G; Alacqua M; Corrao S; Tari M; Arcoraci V
J Am Geriatr Soc; 2008 Jan; 56(1):175-7. PubMed ID: 18184214
[No Abstract] [Full Text] [Related]
28. Lipid goal achievement and trends in lipid-lowering therapy in veterans undergoing carotid endarterectomy.
Fitzgerald TN; Popp C; Dardik A; Federman DG
Vasc Med; 2009 Feb; 14(1):21-7. PubMed ID: 19144776
[TBL] [Abstract][Full Text] [Related]
29. Beyond LDL cholesterol: the role of elevated triglycerides and low HDL cholesterol in residual CVD risk remaining after statin therapy.
Alagona P
Am J Manag Care; 2009 Mar; 15(3 Suppl):S65-73. PubMed ID: 19355805
[TBL] [Abstract][Full Text] [Related]
30. Evaluation of the impact of the recent controversy over statins in France: the EVANS study.
Saib A; Sabbah L; Perdrix L; Blanchard D; Danchin N; Puymirat E
Arch Cardiovasc Dis; 2013 Oct; 106(10):511-6. PubMed ID: 24080324
[TBL] [Abstract][Full Text] [Related]
31. Continuation of statin treatment and all-cause mortality: a population-based cohort study.
Shalev V; Chodick G; Silber H; Kokia E; Jan J; Heymann AD
Arch Intern Med; 2009 Feb; 169(3):260-8. PubMed ID: 19204217
[TBL] [Abstract][Full Text] [Related]
32. Primary prevention of vascular events in patients with high levels of C-reactive protein: the JUPITER study.
Fonseca FA; Izar MC
Expert Rev Cardiovasc Ther; 2009 Sep; 7(9):1041-56. PubMed ID: 19764857
[TBL] [Abstract][Full Text] [Related]
33. Update on statins and other lipid-lowering drugs.
Miller CA
Geriatr Nurs; 2001; 22(5):276-7. PubMed ID: 11606910
[No Abstract] [Full Text] [Related]
34. Statins and the elderly: recent evidence and current indications.
Schiattarella GG; Perrino C; Magliulo F; Ilardi F; Serino F; Trimarco V; Izzo R; Amato B; Terranova C; Cardin F; Militello C; Leosco D; Trimarco B; Esposito G
Aging Clin Exp Res; 2012 Jun; 24(3 Suppl):47-55. PubMed ID: 23160507
[TBL] [Abstract][Full Text] [Related]
35. The gravity of JUPITER (Justification for the Use of Statins in Primary Prevention: An Intervention Trial Evaluating Rosuvastatin).
O'Keefe JH; Carter MD; Lavie CJ; Bell DS
Postgrad Med; 2009 May; 121(3):113-8. PubMed ID: 19491548
[TBL] [Abstract][Full Text] [Related]
36. Pleiotropic effects and cholesterol-lowering therapy.
Shaw SM; Fildes JE; Yonan N; Williams SG
Cardiology; 2009; 112(1):4-12. PubMed ID: 18577880
[TBL] [Abstract][Full Text] [Related]
37. Statins. Evidence of effectiveness in older patients.
Nash DT
Geriatrics; 2003 May; 58(5):35-6, 39-42. PubMed ID: 12756679
[TBL] [Abstract][Full Text] [Related]
38. By Jove! What is a clinician to make of JUPITER?
Kaul S; Morrissey RP; Diamond GA
Arch Intern Med; 2010 Jun; 170(12):1073-7. PubMed ID: 20585074
[No Abstract] [Full Text] [Related]
39. 'Muscle-sparing' statins: preclinical profiles and future clinical use.
Pfefferkorn JA
Curr Opin Investig Drugs; 2009 Mar; 10(3):245-52. PubMed ID: 19333882
[TBL] [Abstract][Full Text] [Related]
40. The JUPITER trial: How will it change clinical practice?
Watson KE
Rev Cardiovasc Med; 2009; 10(2):91-6. PubMed ID: 19593321
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
